Industry
Biotechnology
Oragenics, Inc. develops antibiotics for infectious diseases in the United States. The company engages in the development and commercialization of NT-CoV2-1, an intranasal vaccine candidate that provides immunity from the novel severe acute respiratory syndrome coronavirus; and Terra CoV-2, an intramuscular vaccine candidate that provides immunity from the novel severe acute respiratory syndrome coronavirus. The company's product candidates also comprise LPT3-04, a weight loss candidate; and SMaRT Replacement Therapy, a topical treatment to prevent dental carries. It has a license agreement with Noachis Terra Inc. for licensing of certain specified patent rights and biological materials relating to the use of pre-fusion coronavirus spike proteins; and a collaboration agreement with Precigen, Inc. and ILH Holdings, Inc. for the development and commercialization of MU1140 and related homologs. The company was formerly known as Oragen, Inc. Oragenics, Inc. was incorporated in 1996 and is headquartered in Tampa, Florida.
Loading...
Open
0.33
Mkt cap
4.3M
Volume
2.8M
High
0.43
P/E Ratio
-0.05
52-wk high
7.74
Low
0.32
Div yield
N/A
52-wk low
0.28
Portfolio Pulse from Benzinga Insights
October 14, 2024 | 8:31 pm
Portfolio Pulse from Benzinga Newsdesk
October 09, 2024 | 1:14 pm
Portfolio Pulse from Benzinga Newsdesk
October 09, 2024 | 11:34 am
Portfolio Pulse from Benzinga Newsdesk
October 08, 2024 | 12:46 pm
Portfolio Pulse from Vandana Singh
October 08, 2024 | 12:30 pm
Portfolio Pulse from Benzinga Newsdesk
October 08, 2024 | 12:30 pm
Portfolio Pulse from Benzinga Newsdesk
October 08, 2024 | 12:30 pm
Portfolio Pulse from Avi Kapoor
October 08, 2024 | 10:36 am
Portfolio Pulse from Benzinga Insights
October 07, 2024 | 8:31 pm
Portfolio Pulse from Benzinga Insights
September 25, 2024 | 2:42 pm
All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.